Compare Alcon AG (ALC) vs Deutsche Bank AG (DB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alcon AG vs Deutsche Bank AG — how do they compare? Alcon AG trades at $66.64 (market cap $32.69B), while Deutsche Bank AG trades at $35.39 (market cap $70.38B). The key difference: Deutsche Bank AG is far larger — about 2.2× Alcon AG's market cap, and Deutsche Bank AG pays the higher dividend (3.17%). Which is the better fit depends on your goals.
| ALC | DB | |
|---|---|---|
Market Cap | $32.69B | $70.38B |
Sector | Health | Financials |
52-Week High | $92.22 | $40.33 |
52-Week Low | $62.02 | $28.37 |
Enterprise Value | $36.28B | — |
Dividend Yield | 0.54% | 3.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
Deutsche Bank (DB) trades at $36.64, up 2.18% today, with bullish technical signals from moving averages and ADX indicators. The stock shows strong fundamental momentum with three consecutive quarterly EPS beats and a net income margin of 21.98% for 2025. Recent strategic moves include selling its India retail unit to Kotak to sharpen focus on higher-growth businesses, while maintaining a dividend payout of $1.00 for H1-26.
The outlook remains positive with revenue growth to $32.2B projected for 2026 and a profit margin of 21.97%. Investment opportunities include attractive valuation with P/E of 10.29 and P/B of 0.8, but risks involve negative operating cash flow of -$28.58B in 2024 and competitive pressures from JPMorgan's expansion in Germany.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About Deutsche Bank AG
In July 2019, Deutsche Bank announced another restructuring plan hoping to revitalize revenue, reduce costs, and return to profitability. The largest moving pieces of the new plan is the full exit of global equity sales & trading, the scaling back of its fixed income business, as well as 18,000 FTE reductions until 2022. The remaining core business segments include private banking, corporate banking, asset management, and investment banking.
Read more on DB →
